Comparative study of Sitagliptin versus Metformin as an Initial Monotherapy in newly diagnosed Type 2 Diabetic subjects

Azhar Memon; Kashif Rasheed Shaikh; Muhammad Atif Ata; Umair Ali Soomro; Shumaila Shaikh; Shumail Saeed Siddiqui

Abstract
ABSTRACT

Objective: To study, analyse and compare the pharamacological efficacy of sitagliptin and metfromin in terms of blood glucose and glycated HbA1 in type 2 diaebtic (T2DM) subjects.
Methodology: An observational study was conducted at the Suleman Roshan Medical College from March 2019 to February 2020. A sample of 200 diagnosed cases of type 2 DM, divided into 100 sitaglitin and 100 metformin, was selected according to inclusion criteria. Sample was selected by non-probability convenient sampling. After 12 weeks therapy, the blood samples were taken, centrifuged and sera for biochemcial analysis. Fasting (FBG) and random blood glucose (RBG) and glycated HbA1 (HbA1c) were estimated by standard methods. Data was analyzed on SPSS (ver. 21.0) at 95% CI (P≤0.05).
Results: Age of Sitagliptin group was 50.5±11.5 comapred Metformin group 50.1±15.5 years (P=0.07). FBG in sitagliptin was decreased by 46% vs. 37% in metformin; RBG in sitagliptin was decreased by 90% vs. 69% in metformin and HbA1c decreased by 14.35 in sitagliptin vs. 11.4% in metformin. Nausea, vomiting, diarrhoea and headache was noted in 3%, 3%, 6% and 5% of those taking sitagliptin compared to 19%, 5%, 13% and 11% in metformin treated subjects respectively (P<0.05).
Conclusion: Sitagliptin monotherapy maintained effective glycemic control with fewer complications compared to metformin. Sitagliptin shows fewer chances of nausea, vomiting, diarrhoea and headache.

Key words: Sitagliptin, metformin, glycemic control, type 2 diabetics.

ABOUT JOURNAL About Publisher Contact Us Editorial & Peer Review Process	POLICIES Privacy Policy Editorial Policy Author's Rights and Obligations Conflict of Interest Policy Plagiarism Policy Advertising Policy	STATEMENTS Terms of Use Author's Rights and Obligations Publication Ethics and Publication Malpractice Statement Protection of Research Participants (Statement On Human And Animal Rights) License Information

This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access. The articles in Rawal Medical Journal are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

Indexed in Scopus, Web of Science, WHO Index Medicus IMEMR, Emromedex, Pakmedinet, ExtraMED and Tehqeeqat

How to cite this article

	Open Access and Peer-reviewed
Home Journal Issues Guide for Authors Editorial Board Aims & Scope About Journal News & Announcements